CLYM (Climb Bio) Tariff Resilience Score: 7/10 (As of Jul. 02, 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.59
! 3 Warning Signs
View Full Analysis

What is Climb Bio Tariff Resilience Score?

Climb Bio CLYM -5.27% 22 Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,374 Biotechnology companies, Climb Bio ranks better than 90.39% on this metric.

Climb Bio has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Climb Bio has Biotechnology firm with limited exposure to tariffs. Primarily domestic operations and potential exemptions in healthcare sector.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Climb Bio might have Highly Resilient.

Climb Bio  (NAS:CLYM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Climb Bio Tariff Resilience Score Related Terms

CLYM vs XOMA, CTMX, ALLO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Climb Bio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Climb Bio's Tariff Resilience Score falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Climb Bio (CLYM) has a Tariff Resilience Score of 7 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Climb Bio ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Climb Bio's Tariff Resilience Score too high?
Climb Bio's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Climb Bio's value of 7 is 75% above this industry median. Based on the distribution chart, Climb Bio ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Tariff Resilience Score compare to XOMA and CTMX?
According to the Biotechnology industry distribution chart, Climb Bio ranks #132 out of 1374 companies for Tariff Resilience Score. This places Climb Bio in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Climb Bio's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Climb Bio's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Climb Bio (CLYM), the current Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.59
Price